

## תפקיד נוכחי

2015 ואילך: רופאה בכירה, מכון לאנדוקרינולוגיה, מטבוליזם ויתר לחץ דם. המרכז הרפואי תל-אביב ע"ש סוראסקי, ביה"ח איכילוב.

## ניסיון תעסוקתי

2013-2014: התמחות באנדוקרינולוגיה - המכון לאנדוקרינולוגיה, מטבוליזם ויתר לחץ דם, המרכז הרפואי תל-אביב ע"ש סוראסקי  
 2008-2012: התמחות ברפואה פנימית - מחלקה פנימית י', המרכז הרפואי תל-אביב ע"ש סוראסקי  
 2007-2008: סטאז' במרכז הרפואי תל-אביב ע"ש סוראסקי

## השכלה

2003-2006: תואר שני בניהול מערכות בריאות (M.H.A.) אוניברסיטת בן גוריון - סיום לימודי תואר שני בהצטיינות  
 2000-2006: תואר ד"ר לרפואה (M.D) אוניברסיטת בן גוריון - סיום לימודי תואר ראשון בהצטיינות יתרה. תעודות הערכה/ הצטיינות מחלקתית בעבור כל שנת לימוד

## השתלמויות

2016: Postgraduate course בנושא הורמון גדילה, גוטנברג, שבדיה.  
 2014: בית ספר ליתר לחץ דם, ורנה, בולגריה.  
 2006: אלקטיב בבתי החולים מונטיפיורי וג'אקובי בניו יורק (10 שבועות).

## פרסומים

1. [Low-Dose Cyproterone Acetate Treatment for Transgender Women.](#)  
 Even Zohar N, Sofer Y, Yaish I, Serebro M, Tordjman K, Greenman Y.  
 J Sex Med. 2021 Jul; 18(7):1292-1298. doi:  
 10.1016/j.jsxm.2021.04.008. Epub 2021 Jun 24.  
 PMID: 34176757

2. [The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study.](#)  
Izhakov E, Shacham Y, Serebro M, Yaish I, Marcus Y, Shefer G, Tordjman K, Greenman Y, Stern N, Ziv-Baran T.  
J Clin Med. 2021 Jun 5; 10(11):2504. doi: 10.3390/jcm10112504.  
PMID: 34198795 [Free PMC article.](#)
3. [A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study.](#)  
Yaish I, Azem F, Gutfeld O, Silman Z, Serebro M, Sharon O, Shefer G, Limor R, Stern N, Tordjman KM.  
Thyroid. 2018 Apr; 28(4):522-527. doi: 10.1089/thy.2017.0442. Epub 2018 Mar 13.  
PMID: 29466932
4. [Epidemiologic and microbiologic characteristics of culture-positive spontaneous otorrhea in children with acute otitis media.](#)  
Leibovitz E, Serebro M, Givon-Lavi N, Greenberg D, Broides A, Leiberman A, Dagan R.  
Pediatr Infect Dis J. 2009 May;28(5):381-4. doi: 10.1097/INF.0b013e318194e783.  
PMID: 19319018

### **השתתפות במחקרים קליניים במכון האנדוקריני:**

1. 2015: Non-interventional study for the generation of long term safety and efficacy data of pasireotide s.c. in patients with Cushing's disease (Post-Authorization Safety Study)
2. 2015-2016: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin.
3. 2015-2016: A Phase IIa, randomized, double-blind, placebo (vehicle)-controlled, dose finding trial to assess the safety, tolerability and efficacy of NRD135S.E1 in patients with neuropathic pain associated with diabetes mellitus.
4. 2016: Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
5. 2016: Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.

6. 2016: An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4RKetoconazole) in the Treatment of Endogenous Cushing's Syndrome (SONICS)
7. 2016: A multicenter, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin® FlexPro® in adults with growth hormone deficiency for 35 weeks, followed by a 53-week open-label extension period.
8. 2016: A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
9. 2017: A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatin receptor ligands (SRL) treatment.
10. 2017: A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome (LOGICS)
11. 2018: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period.
12. 2018- Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Individuals.
13. 2018: Long term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS).
14. 2018: SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity.
15. 2018: A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia.
16. 2018: An Open-Label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome (OPTICS).
17. 2019: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL).
18. 2021: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant.
19. 2021: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Efficacy and Safety of Relacorilant.